Mindwalk Holdings Corp. · NASDAQ:HYFT
Mindwalk — ImmunoPrecise Antibodies — Q2 2024 Earnings Presentation
15 slides from Mindwalk's earnings presentation, Dec 14, 2023
Slide 1: FY24 Q2 Earnings Presentation
FY24 Q2 Earnings Presentation December 14, 2023 | ir.ipatherapeutics.com | NASDAQ: IPA
Slide 2: Disclosures
Disclosures Disclaimer This presentation is not, & nothing in it should be construed as, an offer, invitation or recommendation in respect of ImmunoPrecise Antibodies Ltd. (the “Company”) securities, or an offer, invitation or recommendation to sell, or solicitation of an offer to buy, the facilitie
Slide 3: Fiscal Year 2024 Q2 Business Update
Fiscal Year 2024 Q2 Earnings Call Fiscal Year 2024 Q2 Business Update ir.ipatherapeutics.com | NASDAQ:IPA ©2023 ImmunoPrecise Antibodies LTD. All rights reserved. IPA is a trademark of ImmunoPrecise Antibodies LTD. BioStrand is an independently operating subsidiary of ImmunoPrecise Antibodies. 3 Bio
Slide 4: Driven by mission and strategy
Fiscal Year 2024 Q2 Earnings Call Driven by mission and strategy IPA offers end-to-end antibody services encompassing discovery through development, aimed at reducing the risk, cost, and time needed to bring novel therapies to the clinic ir.ipatherapeutics.com | NASDAQ:IPA ©2023 ImmunoPrecise Antibo
Slide 5: Continued growth and financial performance
Fiscal Year 2024 Q2 Earnings Call Momentum through strategic vision Continued growth and financial performance IPA: BioStrand: Talem: • $6.2M revenue - Third consecutive record quarter Recognized Executed Letter early revenue, of Intent to +18.6% revenue increase from Q2 2023 moving toward engage in
Slide 6: Full continuum service offering – fueling growth
Fiscal Year 2024 Q2 Earnings Call Momentum through strategic vision Full continuum service offering – fueling growth Expanded Investing in Sales orders up Utrecht site areas with +83% to meet the highest YOY Q2 market potential demand returns ir.ipatherapeutics.com | NASDAQ:IPA ©2023 ImmunoPrecise A
Slide 7: LENSai commercialization driven by integration
Fiscal Year 2024 Q2 Earnings Call BioStrand Business Update LENSai commercialization driven by integration • Partnered with 19 of top 20 global pharma companies • Integrating technology into full continuum workflows • Product development stemming from working knowledge • Upcoming LENSai launches: Ph
Slide 8: Driving existing assets for return on investments
Fiscal Year 2024 Q2 Earnings Call Talem Business Update Driving existing assets for return on investments • Monetizing existing assets • Major reduction in cash burn • Received and executed Letter of Intent to enter a Material Transfer Agreement ir.ipatherapeutics.com | NASDAQ:IPA ©2023 ImmunoPrecis
Slide 9: IPA New Board of Directors
Fiscal Year 2024 Q2 Earnings Call Track record of success IPA New Board of Directors Mitch Levine Dr. Jennifer Bath Chris Buyse Barry Springer Dirk Witters Chairman of the board ir.ipatherapeutics.com | NASDAQ:IPA ©2023 ImmunoPrecise Antibodies LTD. All rights reserved. IPA is a trademark of ImmunoP
Slide 10: Fiscal Year 2024 Q2 Financial Update
Fiscal Year 2024 Q2 Earnings Call Fiscal Year 2024 Q2 Financial Update ir.ipatherapeutics.com | NASDAQ:IPA ©2023 ImmunoPrecise Antibodies LTD. All rights reserved. IPA is a trademark of ImmunoPrecise Antibodies LTD. BioStrand is an independently operating subsidiary of ImmunoPrecise Antibodies. 10 B
Slide 11: $6.2M total revenue with 19% year-over-year growth
Fiscal Year 2024 Q2 Earnings Call $6.2M total revenue with 19% year-over-year growth $7.0 M $6.2 M $6.0 M $5.7 M $5.6 M $5.2 M $5.2 M $5.2 M $5.0 M $4.7 M $4.6 M $4.7 M $4.8 M $4.0 M $3.0 M $2.0 M $1.0 M $0.0 M Q1 Q2 Q3 Q4 FY24 FY23 FY22 All values listed in CAD. Ir.ipatherapeutics.com | NASDAQ:IPA
Slide 12: Operating Expenses
Fiscal Year 2024 Q2 Earnings Call Operating Expenses Ongoing R&D investment in BioStrand as Talem asset build completes Research & Development Sales & Marketing General & Administrative $6.00 M $0.95 M $4.00 M $5.00 M $0.92 M $3.83 M $5.00 M $3.80 M $0.90 M $4.00 M $3.60 M $3.00 M $0.85 M $0.82 M $3
Slide 13: Net Loss of $2.6M, equivalent to ($0.10) per share
Fiscal Year 2024 Q2 Earnings Call Net Loss of $2.6M, equivalent to ($0.10) per share (basic & diluted) Net Loss Earnings Per Share $0.00 M 0.00 -$1.00 M -$2.62 M -0.05 -0.10 -$2.00 M -0.10 -$3.00 M -$7.35 M -0.15 -0.30 -$4.00 M -0.20 -$5.00 M -0.25 -$6.00 M -0.30 -$7.00 M -$8.00 M -0.35 FY24 Q2 FY23
Slide 14: Unrestricted Cash of $6M with reduced cash burn
Fiscal Year 2024 Q2 Earnings Call Unrestricted Cash of $6M with reduced cash burn Cash on hand Oct 31, 2023* $6.0 M FY24 average quarterly cash burn is $1 million, down from FY23 July 31, 2023 $6.7 M average of $5.6 million and FY22 of $3.1 million April 30, 2023 $8.3 M * Does not include estimated
Slide 15: FY 2024 Q2 Earnings Call
FY 2024 Q2 Earnings Call The HUB of December 14, 2023 | ir.ipatherapeutics.com | NASDAQ: IPA, TSXV: IPA Biotherapeutic ©2023 ImmunoPrecise Antibodies LTD. All rights reserved. IPA is a trademark of ImmunoPrecise Antibodies LTD. BioStrand is an independently operating subsidiary of ImmunoPrecise Anti
ImmunoPrecise Antibodies — Q2 2024 Earnings Presentation on 6ix